Galderma Group initiated buy at HC Wainwright (timing uncertain) (CHF 144.30, -1.60)
Galderma Group reports three-year data from OLYMPIA extension study showing sustained efficacy and favorable safety profile of Nemluvio in moderate-to-severe prurigo nodularis (CHF 145.90, 0.00)
Galderma announces triple approval of new state-of-the-Art Restylane syringe in the EU, the US. and Canada (CHF 144.10, 0.00)
Galderma Group appoints Luigi La Corte as CFO, effective 1-May (CHF 152.20, 0.00)
Galderma Group launches Japan's first OBT-based hyaluronic acid Injectables with Restylane Defyne and Refyne (CHF 148.40, 0.00)
StreetAccount Summary - European pre-market trading update
Galderma announces US FDA acceptance of RelabotulinumtoxinA biologics license application resubmission (CHF 143.90, 0.00)
Galderma Group to present new evidence supporting Sculptra's regenerative body benefits following EU MDR vertification (CHF 153.30, 0.00)
Ipsen confirms Arbitration ruling upholding Ipsen's termination of R&D agreement with Galderma (€133.50, 0.00)
Galderma Group provides update on arbitration case regarding Neuromodulator research and development partnership (CHF 153.30, 0.00)
Powered by FactSet Research Systems Inc.